On September 12, 2025 Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, reported that new preclinical results on its bispecific antibody ATOR-4066 will be presented today at the 9th International Cancer Immunotherapy Conference (CIMT) (Free CIMT Whitepaper) (CICON25), jointly organized in Utrecht, by the Cancer Research Institute (CRI), the European Network for Cancer Immunotherapy (ENCI), and other leading partners (Press release, Alligator Bioscience, SEP 12, 2025, View Source [SID1234655945]). The poster presentation (Poster #253) will take place during Poster Session B, from 12:00–15:00 CEST.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Summary of results
ATOR-4066 is a bispecific antibody designed to activate the immune system against CEACAM5-positive cancers, such as colorectal and gastric cancer. The new preclinical data, in the presentation "ATOR-4066, a Neo-X-Prime bispecific antibody targeting CD40 and CEACAM5, induces strong myeloid and T cell dependent tumor immunity and synergizes with PD-1 blockade," show that ATOR-4066 strongly stimulates both myeloid cells and T cells inside tumors, leading to powerful and durable anti-tumor effects. In preclinical models, ATOR-4066 eliminated established tumors, showed limited immune activation outside the tumor, and demonstrated enhanced efficacy in combination with PD-1 blockade. These findings provide strong support for advancing ATOR-4066 into further development.

"We are excited to present these new preclinical findings demonstrating that ATOR-4066 triggers potent, dual-acting immune responses that translate into strong anti-tumor activity," said Peter Ellmark, CSO at Alligator Bioscience. "ATOR-4066 represents the next step in our mission to develop best-in-class CD40-based therapies and builds directly on the promising clinical progress made with mitazalimab. The data to be presented at CICON25 support the continued development of ATOR-4066 as a differentiated bispecific candidate with potential to transform treatment outcomes in solid tumors."
The poster will be made available on Alligator’s website, following the presentation.

On September 12, 2025 Alkermes plc (Nasdaq: ALKS) reported the appointment of Joshua Reed as Chief Financial Officer (CFO), effective Monday, Sept. 15, 2025 (Press release, Alkermes, SEP 12, 2025, View Source [SID1234655943]). Mr. Reed will report to Richard Pops, Chief Executive Officer of Alkermes, and will join the company’s management committee.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"I’m delighted to be joining Alkermes and look forward to working with Richard and the team to build on Alkermes’ strong financial foundation and advance its strategic priorities with a financial strategy that supports continued innovation, operational excellence and long-term growth," said Mr. Reed.

Mr. Reed brings over 30 years of financial leadership experience, with a strong focus in the biotechnology and pharmaceutical sectors. Most recently, he served as CFO of Omega Therapeutics, a then publicly-traded biotechnology company. Prior to that, he was the CFO at Aldeyra Therapeutics. Earlier in his career, Mr. Reed spent more than a decade at Bristol Myers Squibb, culminating in his role as Vice President and Head of Finance Operations for the U.S. and Puerto Rico. His experience also includes roles at JPMorganChase, Credit Suisse First Boston, and Chase Manhattan Bank.

Mr. Reed currently serves on the board of directors of Scholar Rock Holding Corporation, a publicly-traded biotechnology company. He earned a Bachelor of Science in Finance from Rutgers University and a Master of Business Administration from the University of Michigan’s Ross School of Business.

"We are pleased to welcome Joshua to Alkermes at such an exciting time in our company’s evolution," said Mr. Pops. "Joshua brings a wealth of financial expertise and strategic insight from his extensive experience in the biopharmaceutical industry. We gain his financial acumen and dedication to excellence as we continue to focus on driving strong performance across our commercial business, advancing our pipeline, and delivering long-term shareholder value. I look forward to the positive impact he will have across our organization."

On September 12, 2025 Alkermes plc (Nasdaq: ALKS) reported the appointment of Joshua Reed as Chief Financial Officer (CFO), effective Monday, Sept. 15, 2025 (Press release, Alkermes, SEP 12, 2025, View Source [SID1234655943]). Mr. Reed will report to Richard Pops, Chief Executive Officer of Alkermes, and will join the company’s management committee.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"I’m delighted to be joining Alkermes and look forward to working with Richard and the team to build on Alkermes’ strong financial foundation and advance its strategic priorities with a financial strategy that supports continued innovation, operational excellence and long-term growth," said Mr. Reed.

Mr. Reed brings over 30 years of financial leadership experience, with a strong focus in the biotechnology and pharmaceutical sectors. Most recently, he served as CFO of Omega Therapeutics, a then publicly-traded biotechnology company. Prior to that, he was the CFO at Aldeyra Therapeutics. Earlier in his career, Mr. Reed spent more than a decade at Bristol Myers Squibb, culminating in his role as Vice President and Head of Finance Operations for the U.S. and Puerto Rico. His experience also includes roles at JPMorganChase, Credit Suisse First Boston, and Chase Manhattan Bank.

Mr. Reed currently serves on the board of directors of Scholar Rock Holding Corporation, a publicly-traded biotechnology company. He earned a Bachelor of Science in Finance from Rutgers University and a Master of Business Administration from the University of Michigan’s Ross School of Business.

"We are pleased to welcome Joshua to Alkermes at such an exciting time in our company’s evolution," said Mr. Pops. "Joshua brings a wealth of financial expertise and strategic insight from his extensive experience in the biopharmaceutical industry. We gain his financial acumen and dedication to excellence as we continue to focus on driving strong performance across our commercial business, advancing our pipeline, and delivering long-term shareholder value. I look forward to the positive impact he will have across our organization."

On September 11, 2025 Cellectar Biosciences, Inc. (Nasdaq: CLRB, "Cellectar"), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, and ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, reported a supply agreement for Actinium-225 (Ac-225). The agreement will support the clinical development of Cellectar’s actinium-labeled phospholipid ether (PLE) radiopharmaceutical candidates, including its Phase 1-ready compound, CLR 121225, for the treatment of solid tumors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

CLR 121225 (225Ac-CLR 121225), a novel actinium-labeled PLE, is under investigation for the treatment of solid tumors, including pancreatic cancer. Cellectar’s proprietary PLE delivery platform allows for the design and development of novel radiopharmaceuticals that can selectively target and eradicate cancer cells. ITM is leveraging its two decades of medical isotope manufacturing to scale supplies of Ac-225 to ensure rapid, reliable isotope delivery.

"Our lead alpha-emitting program, CLR 121225, has demonstrated excellent anti-tumor effects in preclinical studies, especially in pancreatic cancer," said James Caruso, chief executive officer of Cellectar. "Our agreement with ITM supports our strategic approach to ensure continuous, high-quality supply of Actinium-225 we need to advance our pipeline candidates and to fully explore the potential benefits of this targeted alpha therapy for cancer patients."

Ac-225 is an important isotope for the development of next-generation radiopharmaceuticals, serving as a powerful alpha-emitting isotope used in targeted cancer therapies. The scarcity of high-quality Ac-225 has slowed the advancement of research and development of Ac-225 based programs. To overcome this challenge and support the timely advancement of its pipeline, Cellectar has constructed a network of Ac-225 suppliers ensuring access to a sufficient supply.

"This agreement reflects our strategic commitment to advancing global access to radiopharmaceuticals," said Dr. Andrew Cavey, chief executive officer of ITM. "We value our partnership with Cellectar and our shared belief in the potential of innovative radiopharmaceutical therapies to significantly improve outcomes for patients with cancer. With more than two decades of leadership in the field, a fully vertically integrated model, and our joint venture, Actineer, ITM is uniquely positioned to meet the growing global demand for this critical isotope."

Under the terms of the agreement, ITM will supply Cellectar with the required quantities to facilitate the clinical development of its therapeutic medical grade radioisotope, Ac-225, produced by Actineer Inc., the joint venture between ITM and Canadian Nuclear Laboratories. Reliable, scalable production sites are crucial to meet the growing demand for Ac-225, given limited supply and manufacturing complexities surrounding the isotope.

(Press release, ITM Isotopen Technologien Munchen, SEP 11, 2025, View Source [SID1234661162])

On September 11, 2025 RadioMedix, Inc., a clinical-stage biotechnology company focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring, and cancer therapy, and Vect-Horus, an expert in the design and development of molecular vectors to facilitate targeted delivery of therapeutic molecules and imaging agents, reported that the first patient has been dosed in an exploratory Investigational New Drug (IND) study evaluating the diagnostic and targeting efficiency of 203Pb-RMX-VH-PIB in patients with Glioblastoma Multiforme (GBM) and Pancreatic Ductal Adenocarcinoma (PDAC) (Press release, Vect-Horus, SEP 11, 2025, View Source [SID1234656105]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Patients impacted by devastating cancers such as GBM and PDAC often have very poor prognosis and limited effective therapies. 203Pb-RMX-VH-PIB, which is able to cross the blood-brain-barrier, could offer a novel approach for targeting both," said Ebrahim S. Delpassand, M.D., Chief Executive Officer of RadioMedix. "This study will provide the first human insights to guide future clinical development of a theranostic radiopharmaceutical which may ultimately help clinical management for patients. As the licensor of 203Pb-RMX-VH-PIB, we remain committed to supporting its development and advancing innovative diagnostic tools that could improve how we understand and treat such challenging diseases."

The diagnostic imaging product 203Pb-RMX-VH-PIB is an agent that targets the Low-Density Lipoprotein Receptor (LDLR), which is overexpressed in solid tumors such as in GBM and PDAC. In preclinical studies, 203Pb-RMX-VH-PIB demonstrated significant tumor accumulation, a pre-requisite for a successful Targeted Radioligand Therapy (TRT).

The objective of this exploratory clinical study is to evaluate the safety, dosimetry, and distribution of 203Pb-RMX-VH-PIB in patients with GBM, the most aggressive and often fatal brain tumor, and PDAC, one of the most chemo-resistant and lethal cancers. This radiotracer will serve as a companion diagnostic for future Targeted Alpha Therapy (TAT) for these cancers.

"We are pleased to announce the initiation of this clinical trial, which is an important milestone for Vect-Horus and demonstrates continuing progress in the collaboration with our partner RadioMedix. We are looking forward to generating clinical data with RadioMedix with the aim of expanding treatment options for patients with GBM and PDAC," said Alexandre Tokay, CEO of Vect-Horus.

RadioMedix and Vect-Horus have a co-development and licensing agreement for theranostic agents.